HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Heart Failure

 

The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.

Cardiology Month in Review: October 2022

October 29, 2022

The October 2022 cardiology month in review features the top content from HFSA 2022, new data related to antithrombotic therapy in atrial fibrillation, and shining a spotlight on the AHA’s scientific statement on patient-reported outcomes in peripheral artery disease.

County-Level Food Insecurity Linked to Increased Heart Failure Mortality Rates

October 26, 2022

An analysis of data from more than 2900 counties in the US is providing clinicians with new insight into the impact of social determinants of health, namely food insecurity, might influence heart failure mortality rates on a population level across the US.

Black Patients with Heart Failure Half as Likely to Receive Device Therapy, Transplant as White Patients

October 19, 2022

Despite no differences in patient preferences, an analysis from the National Institutes of Health suggests Black patients with heart failure were 55% less likely than their White counterparts to receive a ventricular assist device or transplantation.

8-in-10 Medicare Beneficiares Hospitalized with HFpEF Could be Considered Candidates for Dapagliflozin

October 04, 2022

An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.

Dapagliflozin's Benefit in HFpEF Reaches Significance Within 2 Weeks, Study Finds

October 03, 2022

A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.

Sacubitril/Valsartan Use Could Reduce Mitral Regurgitation in HFrEF

October 03, 2022

An analysis of data from the PROVE-HF trial suggests use of sacubitril/valsartan was associated with a reduction in prevalence of mitral regurgitation among patients with heart failure with reduced ejection fraction.

Sotagliflozin Reduces Risk of Recurrent Heart Failure Events

October 02, 2022

New sotagliflozin data at HFSA 2022 provides insight into the apparent reduction in recurrent heart failure events achieved in the SOLOIST-WHF trial. Deepak Bhatt, MD, MPH, provides perspective on the potential role of the dual SGLT1/2 inhibitor, based on trial data, if approved by the US Food and Drug Administration.